💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, fully valued.
JAGSONPAL PHARMACEUTICALS is scored on the pharma / healthcare framework. It keeps a healthy 14.4% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.09×). Free cash flow is worth about 0.8% of its market value.
Over the last 3 years revenue compounded at 7%/yr and profit at 17%/yr. Book value itself has compounded 20%/yr — the hallmark of a genuine compounder. Return on equity is an elite 18.7%. In the latest quarter profit fell 5% versus the prior quarter.
At 33× earnings, the stock sits at the 62nd percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~15%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 31.04 | — | — |
| P/B | 5.79 | 4.11 | worse |
| EV/EBITDA | 19.14 | 19.15 | better |
| ROE | 18.66 | — | — |
| ROCE | 24.6 | 6.87 | better |
| ROA | 15.4 | — | — |
| Quick Ratio | 4.54 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
7% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
Profit is growing faster than revenue (17% vs 7%) — margin expansion is at work.
Operating margin has expanded from 14% to 19% — the business is keeping more of each rupee earned.
ROE at 16% — a respectable return on shareholder capital.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (17% vs -14%) — share dilution is eroding per-share value. -14% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 18% above earlier ones.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 68.8% — heavily owner-operated with strong skin in the game. Promoters added 1.4pp over 4 quarters — creeping acquisition signals conviction.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.